PortalPublikationenHigh discontinuation rate of azathioprine in autoimmune hepa...

High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation

Standard

High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. / Pape, Simon; Gevers, Tom J G; Vrolijk, Jan Maarten; van Hoek, Bart; Bouma, Gerd; van Nieuwkerk, Carin M J; Taubert, Richard; Jaeckel, Elmar; Manns, Michael P; Papp, Maria; Sipeki, Nora; Stickel, Felix; Efe, Cumali; Ozaslan, Ersan; Purnak, Tugrul; Nevens, Frederik; Kessener, Dominik J N; Kahraman, Alisan; Wedemeyer, Heiner; Hartl, Johannes; Schramm, Christoph; Lohse, Ansgar W; Heneghan, Michael A; Drenth, Joost P H.

in: LIVER INT, Jahrgang 40, Nr. 9, 09.2020, S. 2164-2171.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pape, S, Gevers, TJG, Vrolijk, JM, van Hoek, B, Bouma, G, van Nieuwkerk, CMJ, Taubert, R, Jaeckel, E, Manns, MP, Papp, M, Sipeki, N, Stickel, F, Efe, C, Ozaslan, E, Purnak, T, Nevens, F, Kessener, DJN, Kahraman, A, Wedemeyer, H, Hartl, J, Schramm, C, Lohse, AW, Heneghan, MA & Drenth, JPH 2020, 'High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation', LIVER INT, Jg. 40, Nr. 9, S. 2164-2171. https://doi.org/10.1111/liv.14513

APA

Pape, S., Gevers, T. J. G., Vrolijk, J. M., van Hoek, B., Bouma, G., van Nieuwkerk, C. M. J., Taubert, R., Jaeckel, E., Manns, M. P., Papp, M., Sipeki, N., Stickel, F., Efe, C., Ozaslan, E., Purnak, T., Nevens, F., Kessener, D. J. N., Kahraman, A., Wedemeyer, H., ... Drenth, J. P. H. (2020). High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. LIVER INT, 40(9), 2164-2171. https://doi.org/10.1111/liv.14513

Vancouver

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ et al. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. LIVER INT. 2020 Sep;40(9):2164-2171. https://doi.org/10.1111/liv.14513

Bibtex

@article{3773264a3bd244278848cf8840ed0383,
title = "High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation",
abstract = "BACKGROUND: Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2-4 weeks. The safety and efficacy of both strategies have been unexplored.METHODS: We established a cohort of 900 AIH patients from 12 centres in 7 European countries. There were 631 patients who used AZA as part of the therapeutic regimen. We distinguished two groups: patients with early AZA (<2 weeks) or delayed AZA initiation (≥2 weeks). Primary outcome was discontinuation of AZA in the first year of treatment. Cox regression and propensity score matching was performed to determine difference in outcomes between groups.RESULTS: Patients with early AZA initiation had significantly lower transaminases and bilirubin at baseline. Discontinuation rates of AZA did not differ between early and delayed starters (16.6% vs 14.2%), which did not reach statistical significance (hazard ratio 0.97, 95% confidence interval 0.61-1.55, P = .90). Stratification according to baseline disease activity or propensity score matching did not alter the results. Main reason for AZA discontinuation was intolerance to treatment (14.0% vs 13.2%, P = .78) with nausea and vomiting as main side effects. AIH remission rates were comparable among groups.CONCLUSION: The discontinuation rate of AZA in AIH treatment is ~15% in the first year of treatment. Early or delayed AZA initiation does not differ in remission and discontinuation rates in AIH induction therapy. Our data suggest that either strategy may be used as part of AIH treatment.",
author = "Simon Pape and Gevers, {Tom J G} and Vrolijk, {Jan Maarten} and {van Hoek}, Bart and Gerd Bouma and {van Nieuwkerk}, {Carin M J} and Richard Taubert and Elmar Jaeckel and Manns, {Michael P} and Maria Papp and Nora Sipeki and Felix Stickel and Cumali Efe and Ersan Ozaslan and Tugrul Purnak and Frederik Nevens and Kessener, {Dominik J N} and Alisan Kahraman and Heiner Wedemeyer and Johannes Hartl and Christoph Schramm and Lohse, {Ansgar W} and Heneghan, {Michael A} and Drenth, {Joost P H}",
note = "{\textcopyright} 2020 The Authors. Liver International published by John Wiley & Sons Ltd.",
year = "2020",
month = sep,
doi = "10.1111/liv.14513",
language = "English",
volume = "40",
pages = "2164--2171",
journal = "LIVER INT",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation

AU - Pape, Simon

AU - Gevers, Tom J G

AU - Vrolijk, Jan Maarten

AU - van Hoek, Bart

AU - Bouma, Gerd

AU - van Nieuwkerk, Carin M J

AU - Taubert, Richard

AU - Jaeckel, Elmar

AU - Manns, Michael P

AU - Papp, Maria

AU - Sipeki, Nora

AU - Stickel, Felix

AU - Efe, Cumali

AU - Ozaslan, Ersan

AU - Purnak, Tugrul

AU - Nevens, Frederik

AU - Kessener, Dominik J N

AU - Kahraman, Alisan

AU - Wedemeyer, Heiner

AU - Hartl, Johannes

AU - Schramm, Christoph

AU - Lohse, Ansgar W

AU - Heneghan, Michael A

AU - Drenth, Joost P H

N1 - © 2020 The Authors. Liver International published by John Wiley & Sons Ltd.

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2-4 weeks. The safety and efficacy of both strategies have been unexplored.METHODS: We established a cohort of 900 AIH patients from 12 centres in 7 European countries. There were 631 patients who used AZA as part of the therapeutic regimen. We distinguished two groups: patients with early AZA (<2 weeks) or delayed AZA initiation (≥2 weeks). Primary outcome was discontinuation of AZA in the first year of treatment. Cox regression and propensity score matching was performed to determine difference in outcomes between groups.RESULTS: Patients with early AZA initiation had significantly lower transaminases and bilirubin at baseline. Discontinuation rates of AZA did not differ between early and delayed starters (16.6% vs 14.2%), which did not reach statistical significance (hazard ratio 0.97, 95% confidence interval 0.61-1.55, P = .90). Stratification according to baseline disease activity or propensity score matching did not alter the results. Main reason for AZA discontinuation was intolerance to treatment (14.0% vs 13.2%, P = .78) with nausea and vomiting as main side effects. AIH remission rates were comparable among groups.CONCLUSION: The discontinuation rate of AZA in AIH treatment is ~15% in the first year of treatment. Early or delayed AZA initiation does not differ in remission and discontinuation rates in AIH induction therapy. Our data suggest that either strategy may be used as part of AIH treatment.

AB - BACKGROUND: Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2-4 weeks. The safety and efficacy of both strategies have been unexplored.METHODS: We established a cohort of 900 AIH patients from 12 centres in 7 European countries. There were 631 patients who used AZA as part of the therapeutic regimen. We distinguished two groups: patients with early AZA (<2 weeks) or delayed AZA initiation (≥2 weeks). Primary outcome was discontinuation of AZA in the first year of treatment. Cox regression and propensity score matching was performed to determine difference in outcomes between groups.RESULTS: Patients with early AZA initiation had significantly lower transaminases and bilirubin at baseline. Discontinuation rates of AZA did not differ between early and delayed starters (16.6% vs 14.2%), which did not reach statistical significance (hazard ratio 0.97, 95% confidence interval 0.61-1.55, P = .90). Stratification according to baseline disease activity or propensity score matching did not alter the results. Main reason for AZA discontinuation was intolerance to treatment (14.0% vs 13.2%, P = .78) with nausea and vomiting as main side effects. AIH remission rates were comparable among groups.CONCLUSION: The discontinuation rate of AZA in AIH treatment is ~15% in the first year of treatment. Early or delayed AZA initiation does not differ in remission and discontinuation rates in AIH induction therapy. Our data suggest that either strategy may be used as part of AIH treatment.

U2 - 10.1111/liv.14513

DO - 10.1111/liv.14513

M3 - SCORING: Journal article

C2 - 32410363

VL - 40

SP - 2164

EP - 2171

JO - LIVER INT

JF - LIVER INT

SN - 1478-3223

IS - 9

ER -